JACC: CardioOncology : Impact Factor & More
eISSN: 2666-0873pISSN: 2666-0873
Open AccessShare this on:
Key Metrics
CiteScore 
4.5
Eigenfactor
< 0.001
Impact Factor
10 - 15
SJR
Q3Oncology
SNIP
1.12
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JACC: CardioOncology
JACC: CardioOncology Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2500 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | American College of Cardiology |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors |
View less
Planning to publish in JACC: CardioOncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JACC: CardioOncology
Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis.
- 1 Aug 2026
- JACC. CardioOncology
Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective: JACC CardioOncology State-of-the-Art Review.
- 1 Aug 2026
- JACC. CardioOncology
A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.
- 15 Jul 2026
- JACC. CardioOncology
Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk: Insights From Proteomic and Metabolomic Mediators.
- 9 Jul 2026
- JACC. CardioOncology
When "Uptake" Is Organelle Biology: Derisking CRISPR Anthracycline Cardiotoxicity Screens.
- 2 Jul 2026
- JACC. CardioOncology
Refining the Prognostic Interpretation of Myocardial PD-L1 Expression in ICI-Associated Myocarditis.
- 2 Jul 2026
- JACC. CardioOncology
Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis.
- 1 Aug 2026
- JACC. CardioOncology
Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective: JACC CardioOncology State-of-the-Art Review.
- 1 Aug 2026
- JACC. CardioOncology
A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.
- 15 Jul 2026
- JACC. CardioOncology
Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk: Insights From Proteomic and Metabolomic Mediators.
- 9 Jul 2026
- JACC. CardioOncology
When "Uptake" Is Organelle Biology: Derisking CRISPR Anthracycline Cardiotoxicity Screens.
- 2 Jul 2026
- JACC. CardioOncology
Refining the Prognostic Interpretation of Myocardial PD-L1 Expression in ICI-Associated Myocarditis.
- 2 Jul 2026
- JACC. CardioOncology
FAQs on JACC: CardioOncology
How long has JACC: CardioOncology been actively publishing? 
What is the publishing frequency of JACC: CardioOncology?
How many articles did JACC: CardioOncology publish last year?
What is the eISSN & pISSN for JACC: CardioOncology?
What is Citescore for JACC: CardioOncology?
What is SNIP score for JACC: CardioOncology?
What is the SJR for JACC: CardioOncology?
Who is the publisher of JACC: CardioOncology?
